Similar articles

• The role of tumor necrosis factor inhibitors in patients with RA.

  Trethewey P. Trethewey P. JAAPA. 2002 Sep;15(9):23-4, 27, 30 passim. JAAPA. 2002. PMID: 12395668 No abstract available.
• Emerging biologic drugs for the treatment of rheumatoid arthritis.

  Puppo F, Murdaca G, Ghio M, Indiveri F. Puppo F, et al. Autoimmun Rev. 2005 Nov;4(8):537-41. doi: 10.1016/j.autrev.2005.04.016. Autoimmun Rev. 2005. PMID: 16214092 Review.
• [Infliximab in aggressive and refractory rheumatoid arthritis. A pilot study].

  Caramaschi P, Canestrini S, Biasi D, Carletto A, Scambi C, Scarperi A, Bambara LM. Caramaschi P, et al. Recenti Prog Med. 2002 Jan;93(1):19-24. Recenti Prog Med. 2002. PMID: 11850995 Italian.
• Medicare coverage of tumor necrosis factor alpha inhibitors as an influence on physicians' prescribing behavior.

  DeWitt EM, Glick HA, Albert DA, Joffe MM, Wolfe F. DeWitt EM, et al. Arch Intern Med. 2006 Jan 9;166(1):57-63. doi: 10.1001/archinte.166.1.57. Arch Intern Med. 2006. PMID: 16401811
• Infliximab treatment of rheumatoid arthritis.

  Maini SR. Maini SR. Rheum Dis Clin North Am. 2004 May;30(2):329-47, vii. doi: 10.1016/j.rdc.2004.01.009. Rheum Dis Clin North Am. 2004. PMID: 15172044 Review.